Guerbet's Q1 2025 Financial Overview
Quarterly Performance
Guerbet has announced its revenue for the first quarter of 2025, totaling €180.1 million. This amount reflects a decline of 7.1% on a constant exchange rate (CER) basis compared to the previous year. The results highlight a challenging quarter influenced by persistent impacts in France along with the consequences of a challenging comparative base from the prior year.
Diagnostic Imaging experienced a notable decline, with sales down by 8.7% at CER, while Interventional Imaging showcased positive growth, increasing by 5.8% at CER.
Annual Targets Reaffirmed
Despite the downturn in revenue, Guerbet remains optimistic about the financial outlook for the remainder of the year. The company is set to pursue further growth in profitability, forecasting a restated EBITDA margin exceeding 15%. This objective is supported by anticipated revenue growth between 3% and 5% at CER.
Free cash flow is also expected to enter positive territory, which will contribute to the firm’s financial health and strategic flexibility moving forward.
Detailed Revenue Breakdown
As of March 31, 2025, the revenue distribution across geographical areas provided crucial insights:
- EMEA Region: Revenue reached €80.3 million, marking a drop of 4.5% at CER. Much of this decline is attributed to challenges in France, which saw sales contract by 21.2% due to supply reform impacts. However, excluding France, the EMEA region reported a growth of 4.3% at CER.
- Americas: The Americas presented a total revenue of €53.5 million, a reduction of 2.4% at CER. This decline reflects stable volumes affected by slightly lower pricing and past production constraints that led to higher sales levels in previous years.
- Asia: In Asia, sales totaled €44.3 million, down 16.3% at CER. This decline is compared against a high-growth base from Q1 2024 and signifies a mix of order postponements and ongoing market fluctuations in the region.
Activity Segmentation and Performance
Drilling down into specific operational areas, Guerbet's Diagnostic Imaging sector reported reduced sales of €156.2 million, which is an 8.7% drop at CER. Key contributors to this decline were:
- MRI Division: Sales decreased by 1.4% at CER but demonstrated resilience with a growth of 1.4% when excluding the impact from France.
- X-ray Division: This segment experienced a significant decline of 12.4% at CER, a consequence of high levels of sales from previous year catch-up.
On a brighter note, the Interventional Imaging segment saw a revenue increase of 5.8%, bolstered by robust demand and pricing stability.
Strategic Outlook for 2025
Looking ahead, Guerbet plans to build on the established strategies. The company's expectation is for revenue to grow between 3% and 5% for the year, as they anticipate stabilization in France and beneficial comparative performance in the next half of the year.
Moreover, the rigorous cost control measures and improved product mix should lead to enhanced profitability, maintaining the EBITDA margin above 15% for the year, indicating a strong position in the market.
Upcoming Events:
The company is set to publish its H1 2025 revenue on July 24, 2025, post market close.
About Guerbet
Guerbet is recognized as a leader in medical imaging, providing a diverse portfolio that includes pharmaceutical products, medical devices, as well as digital and AI solutions tailored for diagnostic and interventional imaging. With a legacy stretching 98 years in the industry, the company continues to innovate. Guerbet's commitment to research is reflected in its allocation of 9% of revenue towards R&D efforts. As of 2024, the company reported revenues of €841 million and employs over 2,905 individuals worldwide.
Frequently Asked Questions
What were Guerbet's revenues in Q1 2025?
The revenue for Q1 2025 was €180.1 million.
How does the Q1 2025 revenue compare to Q1 2024?
The revenue dropped by 7.1% at constant exchange rates compared to the same quarter in 2024.
What were the performance trends in different geographical regions?
The EMEA region saw a revenue drop, the Americas showed slight decline, while Asia experienced a significant decrease due to various market pressures.
What are Guerbet's profitability targets for 2025?
Guerbet targets an EBITDA margin exceeding 15% with an expected revenue growth of 3%-5% for the year.
What is Guerbet's focus as they move forward?
The company aims to stabilize activity in France, optimize costs, and enhance their product mix to improve profitability.
